Cullinan Therapeutics Inc. (CGEM), a clinical-stage biopharmaceutical company, is scheduled to host an Immunology Day tomorrow, i.e., June 10, 2026. The event will include updates on CLN-978 and Velinotamig, along with related clinical and development progress.
CLN-978 is a potent CD19xCD3 bispecific T cell engager designed to help the immune system target and kill B cells that express CD19. It works by directing T cells to recognize and destroy these cells both in lab and living systems. It is engineered to bind very strongly to CD19, allowing it to effectively target even B cells with low levels of CD19.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
by Prabha Kurup
For comments and feedback: contact editorial@rttnews.com